JP2012524771A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012524771A5 JP2012524771A5 JP2012506583A JP2012506583A JP2012524771A5 JP 2012524771 A5 JP2012524771 A5 JP 2012524771A5 JP 2012506583 A JP2012506583 A JP 2012506583A JP 2012506583 A JP2012506583 A JP 2012506583A JP 2012524771 A5 JP2012524771 A5 JP 2012524771A5
- Authority
- JP
- Japan
- Prior art keywords
- oil
- eur
- composition
- composition according
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims description 25
- 229940079593 drug Drugs 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 14
- 230000007935 neutral effect Effects 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 claims description 2
- 239000000006 Nitroglycerin Substances 0.000 claims description 2
- 229960003711 glyceryl trinitrate Drugs 0.000 claims description 2
- 239000003921 oil Substances 0.000 claims 17
- 235000019198 oils Nutrition 0.000 claims 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 5
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 claims 4
- 229960003511 macrogol Drugs 0.000 claims 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 3
- 125000005456 glyceride group Chemical group 0.000 claims 3
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 claims 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 claims 2
- 239000003240 coconut oil Substances 0.000 claims 2
- 235000019864 coconut oil Nutrition 0.000 claims 2
- 239000003026 cod liver oil Substances 0.000 claims 2
- 235000012716 cod liver oil Nutrition 0.000 claims 2
- GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 claims 2
- DTMGIJFHGGCSLO-FIAQIACWSA-N ethyl (4z,7z,10z,13z,16z,19z)-docosa-4,7,10,13,16,19-hexaenoate;ethyl (5z,8z,11z,14z,17z)-icosa-5,8,11,14,17-pentaenoate Chemical class CCOC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC.CCOC(=O)CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC DTMGIJFHGGCSLO-FIAQIACWSA-N 0.000 claims 2
- 239000010685 fatty oil Substances 0.000 claims 2
- 229960002428 fentanyl Drugs 0.000 claims 2
- 235000021323 fish oil Nutrition 0.000 claims 2
- RZRNAYUHWVFMIP-HXUWFJFHSA-N glycerol monolinoleate Natural products CCCCCCCCC=CCCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-HXUWFJFHSA-N 0.000 claims 2
- 239000010514 hydrogenated cottonseed oil Substances 0.000 claims 2
- 229940057917 medium chain triglycerides Drugs 0.000 claims 2
- 229940124636 opioid drug Drugs 0.000 claims 2
- 239000003346 palm kernel oil Substances 0.000 claims 2
- 235000019865 palm kernel oil Nutrition 0.000 claims 2
- 239000003961 penetration enhancing agent Substances 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 150000003626 triacylglycerols Chemical class 0.000 claims 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims 2
- 235000013311 vegetables Nutrition 0.000 claims 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 230000003078 antioxidant effect Effects 0.000 claims 1
- BLUAFEHZUWYNDE-NNWCWBAJSA-N artemisinin Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2OC(=O)[C@@H]4C BLUAFEHZUWYNDE-NNWCWBAJSA-N 0.000 claims 1
- 229960004191 artemisinin Drugs 0.000 claims 1
- 229930101531 artemisinin Natural products 0.000 claims 1
- 239000004359 castor oil Substances 0.000 claims 1
- 235000019438 castor oil Nutrition 0.000 claims 1
- 239000002285 corn oil Substances 0.000 claims 1
- 235000005687 corn oil Nutrition 0.000 claims 1
- 239000006184 cosolvent Substances 0.000 claims 1
- PWEOPMBMTXREGV-UHFFFAOYSA-N decanoic acid;octanoic acid;propane-1,2-diol Chemical compound CC(O)CO.CCCCCCCC(O)=O.CCCCCCCC(O)=O.CCCCCCCCCC(O)=O.CCCCCCCCCC(O)=O PWEOPMBMTXREGV-UHFFFAOYSA-N 0.000 claims 1
- 239000000796 flavoring agent Substances 0.000 claims 1
- 235000013355 food flavoring agent Nutrition 0.000 claims 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 239000003755 preservative agent Substances 0.000 claims 1
- 230000002335 preservative effect Effects 0.000 claims 1
- FYPMFJGVHOHGLL-UHFFFAOYSA-N probucol Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1SC(C)(C)SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FYPMFJGVHOHGLL-UHFFFAOYSA-N 0.000 claims 1
- 229960003912 probucol Drugs 0.000 claims 1
- 239000010464 refined olive oil Substances 0.000 claims 1
- 239000007921 spray Substances 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
- 229960001967 tacrolimus Drugs 0.000 claims 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 claims 1
- 239000000341 volatile oil Substances 0.000 claims 1
- 238000012377 drug delivery Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/GB2009/050416 WO2010122276A1 (en) | 2009-04-23 | 2009-04-23 | Drug delivery |
| GB0906977.4 | 2009-04-23 | ||
| GB0906977A GB2469792A (en) | 2009-04-23 | 2009-04-23 | Oil-based pharmaceutical formulation for sublingual delivery |
| GBPCT/GB2009/050416 | 2009-04-23 | ||
| PCT/GB2010/050671 WO2010122355A1 (en) | 2009-04-23 | 2010-04-23 | Sublingual pharmaceutical composition comprising a neutral oil |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012524771A JP2012524771A (ja) | 2012-10-18 |
| JP2012524771A5 true JP2012524771A5 (enExample) | 2013-05-09 |
Family
ID=42236683
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012506583A Pending JP2012524771A (ja) | 2009-04-23 | 2010-04-23 | 中性油を含む舌下用の医薬組成物 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20120058158A1 (enExample) |
| EP (1) | EP2421503A1 (enExample) |
| JP (1) | JP2012524771A (enExample) |
| CN (1) | CN102458358A (enExample) |
| AU (1) | AU2010240653A1 (enExample) |
| BR (1) | BRPI1013539A2 (enExample) |
| CA (1) | CA2756879A1 (enExample) |
| IL (1) | IL215454A (enExample) |
| MX (1) | MX2011010835A (enExample) |
| MY (1) | MY167918A (enExample) |
| NZ (1) | NZ595467A (enExample) |
| RU (1) | RU2011139638A (enExample) |
| SG (1) | SG175160A1 (enExample) |
| WO (1) | WO2010122355A1 (enExample) |
| ZA (1) | ZA201107089B (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8852638B2 (en) | 2005-09-30 | 2014-10-07 | Durect Corporation | Sustained release small molecule drug formulation |
| US10512644B2 (en) | 2007-03-12 | 2019-12-24 | Inheris Pharmaceuticals, Inc. | Oligomer-opioid agonist conjugates |
| US8173666B2 (en) | 2007-03-12 | 2012-05-08 | Nektar Therapeutics | Oligomer-opioid agonist conjugates |
| EP2907524A1 (en) | 2007-05-25 | 2015-08-19 | RB Pharmaceuticals Limited | Sustained delivery formulations of risperidone compounds |
| GB0720967D0 (en) * | 2007-10-25 | 2007-12-05 | Protophama Ltd | Anti-material pharmaceutical composition |
| GB2513060B (en) | 2010-06-08 | 2015-01-07 | Rb Pharmaceuticals Ltd | Microparticle buprenorphine suspension |
| US9272044B2 (en) | 2010-06-08 | 2016-03-01 | Indivior Uk Limited | Injectable flowable composition buprenorphine |
| US20130254139A1 (en) * | 2012-03-21 | 2013-09-26 | Xiaoguang Lei | Systems and methods for building a universal intelligent assistant with learning capabilities |
| GB201404139D0 (en) | 2014-03-10 | 2014-04-23 | Rb Pharmaceuticals Ltd | Sustained release buprenorphine solution formulations |
| US10376586B2 (en) * | 2016-02-16 | 2019-08-13 | Entourage Bioscience, LLC | Method and compositions for solubilizing non-polar constituents |
| US11273131B2 (en) | 2016-05-05 | 2022-03-15 | Aquestive Therapeutics, Inc. | Pharmaceutical compositions with enhanced permeation |
| US12427121B2 (en) | 2016-05-05 | 2025-09-30 | Aquestive Therapeutics, Inc. | Enhanced delivery epinephrine compositions |
| US12433850B2 (en) | 2016-05-05 | 2025-10-07 | Aquestive Therapeutics, Inc. | Enhanced delivery epinephrine and prodrug compositions |
| CA3022840A1 (en) | 2016-05-05 | 2017-11-09 | Aquestive Therapeutics, Inc. | Enhanced delivery epinephrine compositions |
| KR102442753B1 (ko) * | 2016-12-26 | 2022-09-16 | 셀릭스 바이오 프라이빗 리미티드 | 만성 통증 치료를 위한 화합물 |
| WO2019067670A1 (en) * | 2017-09-27 | 2019-04-04 | Aquestive Therapeutics, Inc. | EPINEPHRINE AND ENHANCED DELIVERY COMPOSITIONS |
| WO2020136620A1 (en) | 2018-12-29 | 2020-07-02 | 3M Innovative Properties Company | Oral articles and methods of use |
| PL4125843T3 (pl) | 2020-03-31 | 2025-09-22 | Remicine IP B.V. | Leczenie ciężkiego zespołu zapalnego |
| EP4422607A4 (en) | 2021-10-25 | 2025-09-03 | Aquestive Therapeutics Inc | ORAL AND NASAL COMPOSITIONS AND METHODS OF TREATMENT |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE71520T1 (de) * | 1986-03-10 | 1992-02-15 | Burghart Kurt | Pharmazeutische zubereitung sowie verfahren zur herstellung derselben. |
| US5955098A (en) * | 1996-04-12 | 1999-09-21 | Flemington Pharmaceutical Corp. | Buccal non polar spray or capsule |
| US20050281752A1 (en) * | 1997-10-01 | 2005-12-22 | Dugger Harry A Iii | Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system |
| CZ306277B6 (cs) * | 2001-02-14 | 2016-11-09 | Gw Pharma Limited | Pumpičkou aktivovaná kapalná sprejová formulace |
| US8486972B2 (en) * | 2006-01-25 | 2013-07-16 | Insys Therapeutics, Inc. | Sublingual fentanyl spray |
| WO2009020666A1 (en) * | 2007-08-06 | 2009-02-12 | Insys Therapeutics Inc. | Oral cannabinoid liquid formulations and methods of treatment |
| GB0720967D0 (en) * | 2007-10-25 | 2007-12-05 | Protophama Ltd | Anti-material pharmaceutical composition |
| SI2424523T1 (sl) * | 2009-04-23 | 2012-11-30 | Londonpharma Ltd | Podjezična aerosolna formulacija ki vsebuje dihidroartemezinin |
-
2010
- 2010-04-23 EP EP10715336A patent/EP2421503A1/en not_active Withdrawn
- 2010-04-23 MX MX2011010835A patent/MX2011010835A/es active IP Right Grant
- 2010-04-23 SG SG2011073939A patent/SG175160A1/en unknown
- 2010-04-23 CA CA2756879A patent/CA2756879A1/en not_active Abandoned
- 2010-04-23 JP JP2012506583A patent/JP2012524771A/ja active Pending
- 2010-04-23 RU RU2011139638/15A patent/RU2011139638A/ru unknown
- 2010-04-23 NZ NZ595467A patent/NZ595467A/xx not_active IP Right Cessation
- 2010-04-23 CN CN2010800179717A patent/CN102458358A/zh active Pending
- 2010-04-23 US US13/265,825 patent/US20120058158A1/en not_active Abandoned
- 2010-04-23 MY MYPI2011005079A patent/MY167918A/en unknown
- 2010-04-23 BR BRPI1013539A patent/BRPI1013539A2/pt not_active Application Discontinuation
- 2010-04-23 WO PCT/GB2010/050671 patent/WO2010122355A1/en not_active Ceased
- 2010-04-23 AU AU2010240653A patent/AU2010240653A1/en not_active Abandoned
-
2011
- 2011-09-28 ZA ZA2011/07089A patent/ZA201107089B/en unknown
- 2011-10-02 IL IL215454A patent/IL215454A/en active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012524771A5 (enExample) | ||
| RU2011139638A (ru) | Сублингвальная фармацевтическая композиция, содержащая нейтральное масло | |
| JP7250865B2 (ja) | 固溶体組成物および心血管疾患における使用 | |
| JP2022174168A (ja) | ω３脂肪酸の自己乳化組成物 | |
| NZ600720A (en) | A Seamless Capsule For A Liquid Pharmaceutical Composition | |
| JP2015520235A5 (enExample) | ||
| JP2013508296A5 (enExample) | ||
| JP2014509655A5 (enExample) | ||
| Aggarwal et al. | Natural oils as skin permeation enhancers for transdermal delivery of olanzapine: in vitro and in vivo evaluation | |
| JP2015520236A5 (enExample) | ||
| RU2014139008A (ru) | Гормонсодержащая эмульсия, содержащая фосфолипиды криля | |
| WO2009139589A3 (en) | Transnasal anticonvulsive pharmaceutical composition comprising poorly soluble anticonvulsant | |
| RS53507B1 (sr) | Farmaceutska kompozicija protiv malarije | |
| WO2008120711A1 (ja) | タミバロテンカプセル剤 | |
| RU2015102597A (ru) | Липидные композиции рацекадотрила | |
| Goswami et al. | Permeation enhancer for TDDS from natural and synthetic sources: A review | |
| GB2469754A (en) | Sub-lingual drug delivery system using a neutral oil | |
| CA2829015C (en) | Formulation comprising phenylaminopyrimidine derivative as active agent | |
| HRP20160446T1 (hr) | Farmaceutski pripravci koji sadrže derivat kamptotecina | |
| AR084235A1 (es) | Composiciones farmaceuticas que comprenden alisporivir | |
| RU2011127248A (ru) | Экструдаты с игловидными действующими веществами | |
| JP2012524772A (ja) | ジヒドロアルテミシニンを含む舌下スプレー用製剤 | |
| JP2011520883A5 (enExample) | ||
| HK1199396A1 (en) | Oral complex formulation comprising omega-3 fatty acid and hmg-coa reductase inhibitor with improved stability | |
| RU2013121269A (ru) | Фармацевтическая композиция и применение фосфолипида в такой фармацевтической композиции |